



ORIGINAL ARTICLE

Chronic obstructive pulmonary disease exacerbations' management in Portuguese hospitals – EvaluateCOPDpt, a multicentre, observational, prospective study



J. Moita^{a,*}, U. Brito^b, C. Rodrigues^a, L. Ferreira^c, J.R. Vieira^d, A. Catarino^a, A. Morais^e, V. Hespanhol^e, C.R. Cordeiro^{f,g}

^a Pulmonology Unit, Coimbra Hospital and University Centre, Coimbra, Portugal

^b Pulmonology Unit, Algarve Hospital and University Centre, Faro, Portugal

^c Pulmonology Unit, Sousa Martins Hospital, Guarda, Portugal

^d Pulmonology Unit, Garcia de Orta Hospital, Almada, Portugal

^e Pulmonology Unit, São João Hospital and University Centre, Porto, Portugal

^f University Clinic of Pulmonology, Faculty of Medicine, University of Coimbra, Portugal

^g Clinical Academic Centre of Coimbra, Portugal

Received 25 February 2022; accepted 16 July 2022

Available online 15 September 2022

KEYWORDS

Chronic obstructive pulmonary disease;
COPD;
Exacerbations;
Disease management

Abstract

Introduction and Objectives: In order to improve the quality of chronic obstructive pulmonary disease (COPD) patients' care, better knowledge of clinical practice and the factors associated with patient outcomes are needed. This study aimed to evaluate the relation between clinical practice and the outcomes of patients admitted for COPD exacerbations in Portuguese hospitals.

Materials and Methods: Observational, multicentre, prospective study with a 60-days follow-up period, in 11 hospitals, including patients aged ≥ 30 years, admitted to hospital for at least 24 hours due to an acute exacerbation of COPD. Demographic and clinical data were collected, including sex, age, smoking habits, hospitalisations, pulmonary function, comorbidities, COPD symptoms, and treatment. Sixty days after discharge, COPD exacerbations management, outcome measures, and readmission data were evaluated through a structured phone follow-up interview.

Results: 196 patients were included (85.7% male, mean age 71.2 years), the majority admitted through the emergency service. Ex-smokers and current smokers accounted for 51% and 36%, respectively. On admission, 72.4% were on LAMA, 54.6% on LABA, and 45.5% were on LABA/LAMA. Inhaled corticosteroids (ICS) were used in 37.3% and systemic steroids (SCS) in 10.3%. 35.7% had had at least one exacerbation, with hospitalisation, in the previous year. There was no spirometry data for 23.2%. On hospitalisation, 98.5% of patients were treated with oxygen and

* Corresponding author at: Joaquim Moita, Quinta São Tomé, 17, 3D. 3150-109. Condeixa. Portugal.
E-mail address: Joaquimmoita@chuc.min-saude.pt (J. Moita).

38.3% with non-invasive ventilation. Additionally, 93.4% used SCS and 60.2% ICS. Antibiotics were administered to 85.2%. 95.4% of patients were discharged; 9 died, 5 of whom had a COPD-related death. The median length of stay was 12 days for discharged patients and 33 days for patients who died. At discharge, 79.1% were prescribed with LAMA, 63.6% SCS, 61.5% LABA and 55.6% LAMA+LABA. 26.2% were prescribed with ICS+LABA+LAMA. At follow-up, 44.4% had a scheduled medical appointment within the 60 days after being discharged, and 28.3% were later readmitted due to exacerbation, of whom 52.8% were hospitalised.

Conclusions: The severity of COPD, particularly in exacerbations, is directly related to impaired lung function and quality of life, mortality, and significant health system costs. Knowledge about COPD exacerbations' management in acute hospital admissions in Portugal may help stimulate a national discussion and review of existing data to engage clinicians, policymakers, managers, and patients, raising awareness and promoting action on COPD.

© 2022 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Chronic obstructive pulmonary disease (COPD) is a major cause of morbimortality worldwide, imposing substantial individual, social and economic burdens. Its impact is expected to rise in the upcoming decades due to the continued exposure to risk factors and an accelerated ageing population.^{1–7} Although epidemiological data are irregularly distributed worldwide, the estimated worldwide COPD mean prevalence is 13.1% (95% CI 10.2–15.6%), and 12.4% in Europe (95% CI 8.8–16.0%).⁸ With the change of smoking habits in recent decades, and although still higher in men, the prevalence and mortality of COPD have increased more rapidly in women.⁹

Due to its high prevalence and chronicity, COPD causes substantial resource utilisation with frequent visits to clinicians, frequent hospitalisations due to acute exacerbations, and the need for chronic therapy, creating significant challenges for healthcare systems.^{2,5,10}

Available therapy can improve symptoms and quality of life and prevent acute worsening of the disease.⁴ Likewise, COPD-appropriate management can decrease symptoms (especially dyspnea), reduce the frequency and severity of exacerbations, hospitalisations and readmissions, improve health status and exercise capacity, and prolong patient survival.^{5,11–15} Recently, there has been great interest in the study of COPD phenotypes and with the personalization of the treatment of COPD based on a phenotypical approach, there has been a change in non-pharmacological and pharmacological management of COPD.¹⁶

A better knowledge of the clinical performance and the identification of different factors associated with patients' outcomes are crucial to improving the quality of care for COPD patients¹⁷.

Furthermore, understanding all levels of standard practice can provide an opportunity for targeted quality improvement interventions that could significantly impact patients' care.¹⁸

Several observational studies, have shown COPD management in real-life setting and provide useful information for establishing appropriate clinical care. Esteban and colleagues identified that dyspnoea at baseline was the main variable associated with 30-day mortality after an emergency department evaluation for exacerbation of COPD,

followed by the presence of cardiac disease, age, use of inspiratory accessory muscle/ paradoxical breathing, and the Glasgow Coma Scale score.¹⁹ Another study found that the factors associated with a higher probability of hospital admission of COPD patients due to respiratory causes were smoking and receiving oxygen therapy, whereas re-admissions were associated with being men, aged 70 years and over, and a smoker.²⁰ These factors, as shown by Terzano and colleagues have implications to the length and cost of hospitalization.²¹

This study aimed to evaluate the clinical practice, clinical factors, and the outcomes of patients admitted for COPD exacerbations in Portuguese hospitals. Secondary objectives included characterisation of disease profile in hospitalised patients, the assessment of treatment and resources used; patients' outcomes assessment at 60-days after hospital discharge; and compliance with the GOLD guidelines' appraisal.

Material and methods

Study design

Observational, multicentre, prospective study with a 60-days follow-up period.

Population

Male and female patients aged ≥ 30 years, admitted to hospital for at least 24 hours due to an acute exacerbation of COPD, who have given their written informed consent for study participation.

Data collection and study assessments

During the screening phase of 16-weeks, all consecutive cases admitted to hospital with a suspicion of a COPD exacerbation were identified upon admission, and the patients were invited to participate in the study. At discharge, if COPD exacerbation was confirmed as the cause of admission and the eligibility criteria were met, the patient was included in the study. The data were retrospectively recorded).

For eligible patients, demographic and clinical data were collected, including sex, age, patients' referral, smoking habits, hospital readmissions, pulmonary function, comorbidities, and specific data on COPD as COPD symptoms and treatment. At follow-up, 60 ± 7 days after discharge, COPD exacerbations management, outcome measures, and readmission data were evaluated through a structured phone interview. Outcomes included in-hospital mortality, length of hospitalisation, hospital readmissions, and mortality at 60-days after hospital discharge.

Ethical aspects

This study was approved by the study sites' institutional review boards or ethics committees.

The work described has been carried out according to the International Conference on Harmonization of Good Clinical and Pharmacoepidemiological Practices, in agreement with the Declaration of Helsinki and maintaining patients' confidentiality.

Written informed consent was obtained from all individual participants involved in the study.

Statistical analysis

Descriptive statistics were calculated for all variables. Mean, median and interquartile range were used for quantitative variables and the absolute and relative frequencies for qualitative ones. Statistical analysis was performed with R software.

Results

Sites and recruitment

Eleven hospitals participated in the study, and between December 2016 and July 2017, 196 patients were included (Table 1). The follow-up period was complete on 30th September 2017.

Patients' demographics and clinical history

Most patients were male (85.7%), mean age was 71.2 years old and most were admitted through the emergency service

Table 1 Participant hospitals and recruitment.

Sites	n (%)
CHUCB – Hospital Pêro da Covilhã	20 (10.2)
CHULC – Hospital de Santa Marta	15 (7.7)
CHUSJ – Hospital de São João	17 (8.7)
CHTMAD – Hospital S. Pedro	22 (11.2)
CHUA – Hospital de Faro	27 (13.8)
CHUC – Pneumology A	14 (7.1)
CHUC – Pneumology B	26 (13.3)
CHTV – Hospital São Teotónio	7 (3.6)
Hospital Beatriz Ângelo	1 (0.5)
Hospital Garcia de Orta	23 (11.7)
Unidade Local de Saúde da Guarda – Hospital Sousa Martins	24 (12.2)

(76.0%). Ex-smokers and active smokers represented 51.0% and 35.7% of the sample, respectively, and 35.7% had been hospitalized at least once for COPD exacerbation in the preceding year. Charlson's comorbidities index score was between 1 and 3 for 77.5% and ≥4 for 16.8% of the enrolled patients. Regarding respiratory symptoms, 54.1% of the admitted patients presented worsening dyspnea, increased sputum production, and change in sputum colour; 24.5% with only one symptom (96.9% with worsening dyspnea, 71.9% had increased sputum production, and 55.6% a change in sputum colour). The demographic and clinical characteristics of the patients included in the study are summarised in Table 2.

Hospital admission

On admission, most patients (94.4%) reported previous medication. Of these, 72.4% were treated with long-acting anticholinergic receptor antagonists (LAMA) and 54.6% with long-acting β₂-adrenoceptor agonists (LABA). Of the 185 patients who reported previous medication, 53.0% were under ICS + LABA + LAMA, 17.5% were treated with LABA + LAMA, and 10.3% used systemic corticosteroids (SCS) (Table 3). Although patients met the study inclusion criteria, due to informatics difficulties in some hospitals, spirometry data records were missing for 23.2% of the patients.

Hospitalisation

Most patients were on oxygen therapy (98.5%), and 38.3% were treated with non-invasive ventilation. Additionally, 93.4% used SCS and 60.2% ICS. Antibiotics were also a regular part of treatment and were administered to 85.2% of the patients (Table 3).

Nine patients died during hospitalization, five of whom had a COPD-related death. The median length-of-hospitalization (±SD) was 12 ± 10 days for discharged patients (95.4%) and 33 ± 16 days for patients who died.

Hospital discharge

Oxygen therapy was prescribed to 56.7% of discharged patients. At discharge, 79.1% of the patients were prescribed LAMA, 63.6% SCS and 61.5% LABA; 55.6% LAMA + LABA, 51.0% of which were also prescribed an ICS; and 26.2% were prescribed ICS+LABA+ LAMA (Table 3). Spirometry results were available for 5.9% of the patients.

A medical appointment and exams were scheduled within 60 days after discharge for 94.1% (n=176) and 27.3% (n=51) of the discharged patients.

60 days follow-up

Follow-up was completed for 96.3% (n=180) of the discharged patients. Three patients died after hospital discharge; two of these deaths were COPD-related.

Of the 187 discharged patients, 44.4% (n=83) had the medical appointment scheduled at discharge, and 28.3% (n=53) were admitted to the emergency department due to a COPD exacerbation. From these, 52.8% (n=28) were hospitalised. Spirometry results were available for 9.5% of the patients, 75% of whom had a scheduled medical appointment (Table 4).

Table 2 Patients' demographic and clinical data at baseline.

n=196	n (%)	Mean±SD	Min-Max	p25	Median	p75
Demographics						
Sex						
Men	168 (85.7)					
Women	28 (14.3)					
Age, years		71.2±12.0	39-91	63	73	80
Anthropometric measures						
Weight, kg		67.6±16.9	32.0-123.0	55.0	66.0	77.8
Height, m		1.64±0.14	1.42-1.90	1.60	1.64	1.69
BMI, kg/m ²		25.1±6.0	14.2-45.7	21.1	24.5	28.3
Smoking habits						
Ex-smokers	100 (51.0)					
Active smokers	70 (35.7)					
Never-smokers	16 (8.2)					
Passive smokers	3 (1.5)					
Not available	7 (3.6)					
Patients' referral						
Emergency service	149 (76.0)					
Patient's initiative	13 (6.6)					
Intensive care unit	9 (4.6)					
Pulmonology/Imunoalergology	5 (2.6)					
General practice	2 (1.0)					
Other	17 (8.7)					
Unavailable	1 (0.5)					
Number of hospital admissions in the previous year		1.7±0.9	1-5	1	1	2
Charlson index score						
0	11 (5.6)					
1	69 (35.2)					
2	51 (26.0)					
3	32 (16.3)					
4	16 (8.2)					
5	6 (3.1)					
6	8 (4.1)					
7	1 (0.5)					
8	1 (0.5)					
9	1 (0.5)					
Basal spirometry, %						
FVC		72.2±22.7	23.5-130.0	56.1	73.0	89.1
FEV ₁		41.9±19.6	12.5-110.0	27.7	36.8	53.0
FEV ₁ /FVC		44.1±14.4	20.0-77.0	34.8	42.9	54.0
Post bronchodilator spirometry, %						
FVC		77.5±25.6	7.0-142.0	62.0	80.4	93.0
FEV ₁		46.0±22.4	4.0-112.0	30.0	40.6	61.2
FEV ₁ /FVC		44.5±14.9	22.0-87.3	34.7	43.5	53.4

BMI – Body Mass Index, FEV₁ - forced expiratory volume in 1 second, FVC - forced vital capacity, Max – maximum, Min – minimum, n – number of patients, p25 – 25th percentile, p75 – 75th percentile, SD - standard deviation.

Discussion

COPD is a leading cause of death worldwide, representing a substantial and increasing socioeconomic burden.⁶ Since COPD is associated with long-term exposure to toxic gases and particles, more people will express the long-term effects of exposure to risk factors as longevity increases.^{1,2,6} COPD prevalence is expected to rise over the next 40 years: by 2060 over 5.4 million deaths per year from COPD and related conditions are estimated.^{6,22}

Disease clinical course can vary from years of stability to devastating acute exacerbations and respiratory failure,

symptoms ranging from chronic productive cough to debilitating dyspnea.²³ An increasingly severe inflammation characterises disease worsening during stable condition and by an intensifying frequency of exacerbations, the most relevant event affecting COPD mortality.^{6,11,24}

The severity of COPD is directly related to the cost of care, and the cost increases as the disease progress. COPD exacerbations are a major cause of the high 30-day hospital readmission rates associated with COPD.¹⁴ Severe COPD exacerbations that result in hospitalisation can be up to 60 times more expensive than mild or moderate exacerbations managed by primary care services.²⁵ Moreover,

Table 3 Treatment at hospital admission (last 30 days), during hospitalisation, and at hospital discharge.

n (%)	Hospital admission n=185 previously treated	Hospitalisation n=196	Hospital discharge n=187
SABA	54 (29.2)	185 (94.4)	61 (32.6)
LABA	101 (54.6)		115 (61.5)
SAMA	34 (18.4)	189 (96.4)	33 (17.6)
LAMA	134 (72.4)		148 (79.1)
ICS+LABA	82 (44.3)		74 (39.6)
ICS	69 (37.3)	118 (60.2)	66 (35.3)
SCS	19 (10.3)	183 (93.4)	119 (63.6)
Theophylline			
Oral	66 (35.7)		77 (41.2)
IV		49 (25.0)	
Antibiotics	24 (13.0)	167 (85.2)	25 (13.4)
Ventilation		79 (40.3)	
NIMV	33 (17.8)	75 (38.3)	54 (28.9)
Invasive ventilation		3 (1.5)	
Invasive+NIMV		1 (0.5)	
Oxygen therapy	82 (44.3)	193 (98.5)	106 (56.7)
Diuretics		117 (59.7)	
Other		67 (34.2)	44 (23.5)

ICS - inhaled corticosteroids, IV – intravenous, LABA - long-acting β 2-adrenoceptor, LAMA - long-acting muscarinic receptor antagonists, NIMV - noninvasive mechanical ventilation, SABA - short-acting beta-agonist, SAMA - short-acting anticholinergic, SCS - systemic corticosteroids.

exacerbations are associated with impaired lung function and quality of life, mortality, and significant health system costs, accounting for the greatest proportion of the total COPD burden on healthcare systems.^{6,7,14,18,26} Morbidity measures traditionally include physician visits, emergency department visits, and hospitalizations. Available data indicate that COPD morbidity increases with age and may be affected by concurrent chronic conditions that are smoking-, ageing- and COPD-related, which may interfere with disease management and are the primary drivers of hospitalisations, and costs for patients with COPD.^{6,27–30}

Patients with COPD have a mortality rate higher than the general population, depending on their disease severity.^{31,32} However, the reduced accuracy of mortality data is associated with the under-recognition and under-diagnosis of COPD, which, together with the uncertainty of diagnosis, contribute to underestimating the disease and its burden.^{2,6,26,33} The high prevalence of COPD coupled with the widespread under-recognition and under-diagnosis of the disease stresses the need to raise COPD awareness.^{34,35}

Aiming to know the Portuguese reality regarding COPD, COPD exacerbations and its management, and to compare it

with the GOLD guidelines, this study analysed the participating hospitals' clinical outcomes and organisational data, providing evidence to support a better organization of patients' care and improved use of resources within Portugal.

Consistently with the literature, the patients included in the study were mostly older men (mean age 71 years old, male to female ratio 6:1), a third of whom still smoked, with moderate to severe spirometric disease, a history of hospitalisation for COPD exacerbations and several comorbidities.

Readmissions for recurrence of exacerbations in this population were also frequent, as found by the European COPD audit involving > 400 hospitals that reported a 90-day readmission rate of 35.1%.³⁶ Similar results were found in the ECLIPSE study, in which COPD exacerbations requiring hospital admission were relatively frequent events occurring in about 30% of patients during the 3-year follow-up.³⁷ In Portugal, frequent acute exacerbations were reported by 38.0% of stable COPD outpatients over 40 years old.³⁸ The mortality was lower than in previous studies involving these patients (exacerbators with poor lung function).³⁷ This difference might be explained by the more common use of non-invasive ventilation in Portuguese hospitals, shown to reduce

Table 4 Spirometric data at hospital discharge.

%	Mean±SD	Min-Max	p25	Median	p75
Hospital discharge, n=187					
FVC	74.6±25.3	59.0-100.0	63.5	70.0	83.5
FEV ₁	49.5±21.1	21.0-72.0	43.5	53.0	59.0
FEV ₁ /FVC	48.0±19.1	27.0-70.0	40.0	48.0	55.0

FEV₁ - forced expiratory volume in 1 second, FVC - forced vital capacity, Max – maximum, Min – minimum, n – number of patients, p25 – 25th percentile, p75 – 75th percentile, SD - standard deviation.

mortality in COPD patients.^{39,40} Nasal high flow oxygen therapy has been used for the management of respiratory failure, complementarily and as an alternative non-invasive respiratory support.⁴¹ However, little and limited evidence for improved clinical outcomes is currently available.

Telemonitoring can be important to predict exacerbations by monitoring symptoms and biological variables such as oximetry, physical activity and temperature. It may also be useful in post-exacerbation discharge and to avoid re-aggravation of symptoms and re-exacerbations.⁴²

Compliance with GOLD guidelines regarding diagnosis was established, as COPD diagnosis was considered for patients with dyspnea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease, and a post-bronchodilator $FEC_1/FVC < 0.70$ confirming the presence of persistent airflow limitation. To define therapy, COPD assessment must consider the presence and severity of spirometric abnormalities, current nature and magnitude of patients' symptoms, exacerbation history, and risk of future events, namely exacerbations, hospital admissions, death, and presence of comorbidities.¹²

Pharmacologic therapy for COPD is used to treat symptoms, reduce the frequency and severity of exacerbations, and improve exercise tolerance and health status. The factors associated with successful treatment should be considered, not only those relying on patients, but also on health-care providers and on the relation between them. One study in Portuguese COPD patients showed that the adherence to medication was higher in patients with more symptoms and more obstructed, whereas previous COPD exacerbations improved prescribers' adherence to treatment guidelines.⁴³ However, it failed to prove a positive association between non-adherence to medication, inhalers mishandling or prescribers' non-adherence to GOLD strategy with symptoms, exacerbations, and airflow limitation.⁴³

In this study, the medications used to treat COPD included bronchodilators LABAs and/or LAMAs and ICS, and recommended treatments ranged from a single short- or long-acting bronchodilator to combinations of two bronchodilators and ICS. This is compliant with the international guidelines regarding in-hospital treatment and shows a high standard of care.^{6,12,26,44}

The small sample size is the main limitation of the study. Although the incidence of COPD is high, the Portuguese centres still have some difficulties to overcome in the development of clinical investigation studies, including the low organisational capacity which causes some barriers to the recruitment of patients. Additionally, in some hospitals, these organisational problems include difficulties with informatics, and there was a lack of information, namely spirometric data, not because they did not exist, but because they were unavailable at the moment of data registry for the study. The development of studies with these characteristics may help to professionalise clinical investigation and, ultimately, with more knowledge about the global panorama, to improve patients' care.

Conclusions

The presented COPD study evaluated COPD exacerbations' management in acute hospital admissions in Portugal,

aiming to raise the standards of care to a level consistent with the GOLD management guidelines. Furthermore, the results obtained from this study may help stimulate a national discussion and review of existing data to engage clinicians, policymakers, managers, and patients, raising awareness and promoting action on COPD.

Declaration of competing interest

All authors declare no conflict of interest related to the manuscript.

References

1. European Respiratory Society. Chronic obstructive pulmonary disease. European Lung White Book; <https://www.erswhite-book.org/chapters/chronic-obstructive-pulmonary-disease/> [accessed 12 October 2021].
2. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. *Lancet*. 2007;370:741–50. [https://doi.org/10.1016/S0140-6736\(07\)61377-4](https://doi.org/10.1016/S0140-6736(07)61377-4).
3. Xie M, Liu X, Cao X, Guo M, Li X. Trends in prevalence and incidence of chronic respiratory diseases from 1990 to 2017. *Respir Res*. 2020;21:49. <https://doi.org/10.1186/s12931-020-1291-8>.
4. Ntritsos G, Franek J, Belbasis L, Christou MA, Markozannes G, Altman P, et al. Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis. *Int J Chron Obstruct Pulmon Dis*. 2018;13:1507–14. <https://doi.org/10.2147/COPD.S146390>.
5. López-Campos JL, Tan W, Soriano JB. Global burden of COPD. *Respirology*. 2016;21:14–23. <https://doi.org/10.1111/resp.12660>.
6. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2021 Report, https://gold-copd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.0-11Nov20_WMV.pdf; 2021 [accessed 12 October 2021].
7. Orozco-Beltrán D, Arriero-Marin JM, Carratalá-Munuera C, Soler-Cataluña JJ, Lopez-Pineda A, Gil-Guillén VF, et al. Trends in hospital admissions for chronic obstructive pulmonary disease in men and women in Spain, 1998 to 2018. *J Clin Med*. 2021;10:1529. <https://doi.org/10.3390/jcm10071529>.
8. Blanco I, Diego I, Bueno P, Casas-Maldonado F, Miravittles M. Geographic distribution of COPD prevalence in the world displayed by Geographic Information System maps. *Eur Respir J*. 2019;54:1900610. <https://doi.org/10.1183/13993003.00610-2019>.
9. Aryal S, Diaz-Guzman E, Mannino DM. COPD and gender differences: an update. *Transl Res*. 2013;162:208–18.
10. Soriano JB, Abajobir AA, Abate KH, Abera SF, Agrawal A, Ahmed MB, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet Respir Med*. 2017;5:691–706. [https://doi.org/10.1016/S2213-2600\(17\)30293-X](https://doi.org/10.1016/S2213-2600(17)30293-X).
11. Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. *Lancet*. 2006;367:1216–9. [https://doi.org/10.1016/S0140-6736\(06\)68516-4](https://doi.org/10.1016/S0140-6736(06)68516-4).
12. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report, <https://>

- goldcopd.org/wp-content/uploads/2017/02/wms-GOLD-2017-FINAL.pdf; 2017 [accessed 12 October 2021].
13. Miravittles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. *Respir Res.* 2017;18:67. <https://doi.org/10.1186/s12931-017-0548-3>.
 14. Bollmeier SG, Hartmann AP. Management of chronic obstructive pulmonary disease: a review focusing on exacerbations. *Am J Heal Pharm.* 2020;77:259–68. <https://doi.org/10.1093/ajhp/zxz306>.
 15. Celi A, Latorre M, Paggiaro P, Pistelli R. Chronic obstructive pulmonary disease: moving from symptom relief to mortality reduction. *Ther Adv Chronic Dis.* 2021;12:204062232110140. <https://doi.org/10.1177/20406223211014028>.
 16. Corlateanu A, Mendez Y, Wang Y, Garnica R de JA, Botnaru V, Siafakas N. Chronic obstructive pulmonary disease and phenotypes: a state-of-the-art. *Pulmonology.* 2020;26:95–100.
 17. López-Campos JL, Hartl S, Pozo-Rodríguez F, Roberts CM. European COPD Audit: design, organisation of work and methodology. *Eur Respir J.* 2013;41:270–6. <https://doi.org/10.1183/09031936.00021812>.
 18. Roberts CM, Lopez-Campos JL, Pozo-Rodríguez F, Hartl S. European hospital adherence to GOLD recommendations for chronic obstructive pulmonary disease (COPD) exacerbation admissions. *Thorax.* 2013;68:1169–71. <https://doi.org/10.1136/thoraxjnl-2013-203465>.
 19. Esteban C, Arostegui I, Garcia-Gutierrez S, Gonzalez N, Lafuente I, Bare M, et al. A decision tree to assess short-term mortality after an emergency department visit for an exacerbation of COPD: a cohort study. *Respir Res.* 2015;16. <https://doi.org/10.1186/S12931-015-0313-4>.
 20. López-Pardo ME, Candal-Pedreira C, Valdés-Cuadrado L, Represas-Represas C, Ruano-Ravina A, Pérez-Ríos M. Factors related with hospital attendance and mortality in patients with COPD: a case-control study in a real-life setting. *Int J Chron Obstruct Pulmon Dis.* 2022;17:809–19. <https://doi.org/10.2147/COPD.S355236>.
 21. Terzano C, Colamesta V, Unim B, Romani S, Meneghini A, Volpe G, et al. Chronic obstructive pulmonary disease (COPD) exacerbation: impact of comorbidities on length and costs during hospitalization. *Eur Rev Med Pharmacol Sci.* 2017;21:3680–9.
 22. World Health Organization. Updated WHO projections of mortality and causes of death 2016–2060. 2018;2016:1–26.
 23. Lowe KE, Regan EA, Anzueto A, Austin E, Austin JHM, Beaty TH, et al. COPDGene® 2019: redefining the diagnosis of chronic obstructive pulmonary disease. *Chronic Obstr Pulm Dis.* 2019;6:384–99. <https://doi.org/10.15326/jcopdf.6.5.2019.0149>.
 24. Tzanakis Nikos N, Fotis P, Hillas G. Acute exacerbation of COPD: is it the “stroke of the lungs”? *Int J Chron Obstruct Pulmon Dis.* 2016;11:1579–86. <https://doi.org/10.2147/COPD.S106160>.
 25. Kong CW, Wilkinson TM. Predicting and preventing hospital readmission for exacerbations of COPD. *ERJ Open Res.* 2020;6:00325–2019. <https://doi.org/10.1183/23120541.00325-2019>.
 26. Vogelmeier CF, Román-Rodríguez M, Singh D, Han MK, Rodríguez-Roisin R, Ferguson GT. Goals of COPD treatment: focus on symptoms and exacerbations. *Respir Med.* 2020;166:105938. <https://doi.org/10.1016/j.rmed.2020.105938>.
 27. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. *Eur Respir J.* 2006;28:523–32. <https://doi.org/10.1183/09031936.06.00124605>.
 28. Quach A, Giovannelli J, Chérot-Kornobis N, Ciuchete A, Clément G, Matran R, et al. Prevalence and underdiagnosis of airway obstruction among middle-aged adults in northern France: The ELISABET study 2011–2013. *Respir Med.* 2015;109:1553–61. <https://doi.org/10.1016/j.rmed.2015.10.012>.
 29. Menezes AMB, Perez-Padilla R, Jardim JB, Muiño A, Lopez MV, Valdivia G, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. *Lancet.* 2005;366:1875–81. [https://doi.org/10.1016/S0140-6736\(05\)67632-5](https://doi.org/10.1016/S0140-6736(05)67632-5).
 30. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. *Am J Respir Crit Care Med.* 2017;195:557–82. <https://doi.org/10.1164/rccm.201701-0218PP>.
 31. Soriano JB, Maier WC, Egger P, Visick G, Thakrar B, Sykes J, et al. Recent trends in physician diagnosed COPD in women and men in the UK. *Thorax.* 2000;55:789–94. <https://doi.org/10.1136/THORAX.55.9.789>.
 32. Afonso ASM, Verhamme KMC, Sturkenboom MCJM, Brusselle GGO. COPD in the general population: prevalence, incidence and survival. *Respir Med.* 2011;105:1872–84. <https://doi.org/10.1016/J.RMED.2011.06.012>.
 33. Duong M, Islam S, Rangarajan S, Teo K, O’Byrne PM, Schünemann HJ, et al. Global differences in lung function by region (PURE): an international, community-based prospective study. *Lancet Respir Med.* 2013;1:599–609. [https://doi.org/10.1016/S2213-2600\(13\)70164-4](https://doi.org/10.1016/S2213-2600(13)70164-4).
 34. Bárbara C, Rodrigues F, Dias H, Cardoso J, Almeida J, Matos MJ, et al. Prevalência da doença pulmonar obstrutiva crónica em Lisboa, Portugal: estudo Burden of Obstructive Lung Disease. *Rev Port Pneumol.* 2013;19:96–105. <https://doi.org/10.1016/j.rppneu.2012.11.004>.
 35. Pires N, Pinto P, Marçal N, Ferreira AJ, Rodrigues C, Bárbara C. Pharmacological treatment of COPD – New evidence. *Pulmonology.* 2019;25:90–6. <https://doi.org/10.1016/j.pulmoe.2018.10.005>.
 36. Welte T. Acute exacerbation in COPD: we must do more. *Eur Respir J.* 2016;47:14–5. <https://doi.org/10.1183/13993003.01981-2015>.
 37. Müllerova H, Maselli DJ, Locantore N, Vestbo J, Hurst JR, Wedzicha JA, et al. Hospitalized exacerbations of COPD. *Chest.* 2015;147:999–1007. <https://doi.org/10.1378/chest.14-0655>.
 38. Duarte-de-Araújo A, Teixeira P, Hespagnol V, Correia-de-Sousa J. Characterisation of morbidity in a COPD hospital cohort. *Pulmonology.* 2019;25:200–7. <https://doi.org/10.1016/j.pulmoe.2019.02.010>.
 39. Sainaghi PP, Colombo D, Re A, Bellan M, Sola D, Balbo PE, et al. Natural history and risk stratification of patients undergoing non-invasive ventilation in a non-ICU setting for severe COPD exacerbations. *Intern Emerg Med.* 2016;11:969–75. <https://doi.org/10.1007/s11739-016-1473-z>.
 40. Osadnik CR, Tee VS, Carson-Chahhoud K V, Picot J, Wedzicha JA, Smith BJ. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2017;2017. <https://doi.org/10.1002/14651858.CD004104.pub4>.
 41. Vega ML, Pisani L. Nasal high flow oxygen in acute respiratory failure. *Pulmonology.* 2021;27:240–7.
 42. Angelucci A, Aliverti A. Telemonitoring systems for respiratory patients: technological aspects. *Pulmonology.* 2020;26:221–32.
 43. Duarte-de-Araújo A, Teixeira P, Hespagnol V, Correia-de-Sousa J. COPD: Analysing factors associated with a successful treatment. *Pulmonology.* 2020;26:66–72. <https://doi.org/10.1016/J.PULMOE.2019.05.012>.
 44. Rodrigues C, Alfaro T, Fernandes L, Ferreira P, Silva S, Costa JC, et al. Does practice follow evidence-based guidelines? Adherence to GOLD guidelines in Portugal. *Pulmonology.* 2019;25:177–9. <https://doi.org/10.1016/j.pulmoe.2019.02.011>.